secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0000950170-21-003725
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion reports Q3 net loss $11.3M, cash $63M; pipeline advances in CIAS, ADv, MELAS
--------------------------------------------------------------------------------

- Net loss of $11.3M improved from $18.8M in Q3 2020; R&D expenses down to $7.0M.
- Cash, cash equivalents, and restricted cash $63M, down from $70M at June 30, 2021.
- First patients enrolled in CIAS study (CY6463); patient screening underway in ADv study.
- MELAS study enrollment slowed by COVID-19; topline clinical results expected H1 2022.
- G&A expenses decreased to $4.6M from $8.0M, driven by lower salaries and financing fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000095017021003725/0000950170-21-003725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000095017021003725/cycn-20211109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer